Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellectis S.A. (NASDAQ: CLLS).

Full DD Report for CLLS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLLS)

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative
Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1...
Source: SeekingAlpha
Date: October, 18 2018 08:49
New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc. (NASDAQ:ESPR), Summit Therapeutics PLC (NASDA...
Source: GlobeNewswire
Date: October, 17 2018 08:10
A Rough Summer Has Knocked Calyxt Down
So far, not so good for my late June high-risk/high-reward call on Calyxt ( CLXT ). The “high risk” part has certainly come through promptly, but shareholders have seen the shares sell off about 25% after a summer that certainly offered more bad news than good, highlighted by...
Source: SeekingAlpha
Date: October, 05 2018 09:13
Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment
NetworkNewsWire Editorial Coverage : Personalized treatment for advanced breast cancer is a massive global medical need. According to latest figures from the Centers for Disease Control, in the United States alone more than 41,000 women die from breast cancer each year. Hope is on the horizon...
Source: NetworkNewsWire
Date: October, 02 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1828.5529.4929.7228.5364158,903
2018-05-1728.5529.4929.7228.5364158,053
2017-02-0218.4018.32518.5018.2543,251
2017-02-0118.1918.5018.64718.1657,216
2017-01-3117.5418.2418.4717.4299,352

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-148,45017,83047.3920Short
2018-12-1313,80723,80757.9955Short
2018-12-122,7549,32029.5494Cover
2018-12-1121,59531,03069.5939Short
2018-12-1010,33629,23435.3561Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLLS.


About Cellectis S.A. (NASDAQ: CLLS)

Logo for Cellectis S.A. (NASDAQ: CLLS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CLLS)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 10 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 01 2018
      Post-effective amendment to an S-8 filing
      Filing Type: S-8 POSFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 11 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 10 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 10 2018

       

       


      Daily Technical Chart for (NASDAQ: CLLS)

      Daily Technical Chart for (NASDAQ: CLLS)


      Stay tuned for daily updates and more on (NASDAQ: CLLS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CLLS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLLS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLLS and does not buy, sell, or trade any shares of CLLS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/